A Review on Application of Nanoadjuvants as Delivery Carrier
Application of Nanoadjuvants as Delivery Carrier
Worldwide immunization can save millions of peoples to lives year by using the vaccines. The subunit of antigen components is manufactured which can stimulate the immune system by providing specific immunity against specific diseases. Subunit vaccines have many advantages like as high safety profile but having limited ability to provide immunogenicity. These traditional subunit vaccine activates only innate immunity, encourage cell-mediated transport of antigen to lymphoid tissues. Newly nano-adjuvants based vaccines carrier systems like liposomes, virosome, micelles, polymeric particles, protein, and peptides are developed by using various substances like viral proteins, polymer and polystyrene having immanent adjuvanticity and also provide exalted capability in manufacturing subunit vaccines. It has chromospheres substances that have various properties such as targeted, anti-damaging and caliber to lead immune reactions towards Th1 and Th2 route, which is an important feature for humoral as well as cellular immunity. The whole thing based on the carrier system, role of nano-adjuvants, its pharmacokinetics and distribution in the body system. It has the ability to provide antigen-specific immunity to both systemic as well as mucosal by different vaccination passage. Also, the nano-adjuvants based vaccine suggested that direct targeting of antigen to improve the vaccine potency without sacrificing safety.
2. Carino GP. Vaccine Delivery. Mathiowitz E, editor. Encyclopedia of Controlled. Drug Delivery. 1999; 04:996-997.
3. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Developments in biological standardization. 1998; 92:63-78.
4. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010; 9:1095-1107.
5. Schuch RA, Oliveira TL, Collares TF, Monte LG, RoigInda G, Dellagostin OA, Vendruscolo CT, Moreira AS, Hartwig DD. The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro. BioMed Research International. 2017; 24:1-9.
6. Pasquale AD, Preiss S, Da Silva FT, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015; 3(2):320-43
7. Lee S, Nguyen MT. Recent Advances of Vaccine Adjuvants for Infectious Diseases. Immune Netw. 2015; 15(2):51-57.
8. Bekiaris V, Persson EK, Agace WW. Intestinal dendritic cells in the regulation of mucosal immunity. Immunological review. 2014; 12:86-101.
9. Kato LM, Kawamoto S, Maruya M, Fagarasan, S. The role of the adaptive immune system in regulation of gut microbiota. Immunological review. 2014; 21:67-75.
10. Kalra N, Dhanya V, Saini V, Jeyabalan G. Virosomes: As a Drug Delivery Carrier. American Journal of Advanced Drug Delivery. 2013; 1:029-035.
11. Karshalm KS, Anderson P, Peril Y, Christenseen D. Liposomal vaccine delivery. An article in expert opinion on drug delivery. 2011; 8(4):505-519.
12. Pardakhty A, Moazenil E. Nano-niosomes in drug vaccine and gene delivery: A rapid overview. Nanomedicine. 2012; 1:1-6.
13. Mohapatra SS. Mucosal gene expression vaccine: A novel strategy for respiratory syncytial virus. Pediatr Infect Dis. 2003; 21:S100-3.
14. Liau J, Prestidge CA, Hook S, Barnes TJ. Development of a multi-compartmental oral vaccine delivery system. ?Europ J. of Pceutics. Bio-Pceutics. 2015; 97:15-21.
15. Cabral H, Kotaoka K. Multifunctional nano assembles of block copolymers for future cancer therapy. Science and Technology of Advanced Materials. 2010; 10:1-9.
16. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Human vaccines & immunotherapeutics. 2013; 9(12):2584-2590.
17. Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: a review. International journal of pharmaceutical investigation. 2011; 1(2):53-64.
18. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Therapeutic advances in vaccines. 2014; 2(6):159-182.
19. Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. International journal of pharmaceutics. 2005; 299(1-2):155-166.
20. Tlaskalova-Hogenova H, Tucková L, Lodinová-Zádniková R, Stepankova, R. Mucosal Immunity: Its Role in Defense and Allergy. International Archives of Allergy and Immunology. 2002; 128(2):77-89.
21. Amselem S, Alving CR, Domb AJ. Polymeric biodegradable lipospheres™ as vaccine delivery systems. Polymers for Advanced Technologies. 1993; 3(6):351-357.
22. Shi S, Hickey AJ. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10. 4-Ag 85B. Pharmaceutical research. 2010; 27(2):350-360.
23. Dineshkumar B, Dhanaraj SA, Santhi K, Vijayan P, Chandrasekhar R. Single dose vaccine delivery system of tetanus toxoid formulation based on chitosan microspheres. International Journal of Advances in Pharmaceutical Sciences. 2010; 1(1):42-49.
24. Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston AP, De Rose R, Kent SJ. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. Acs Nano. 2009; 3(11):3391-3400.
25. Koutsonanos DG., del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I. Transdermal influenza immunization with vaccine-coated microneedle arrays. Plos One. 2009; 4(3):4773-4781.
26. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert review of vaccines. 2008; 7(8):1201-1214.
27. Ada G, Assaad FA, Blanden RV, Bloom BR, Brown F, Schild GC, Torrigiani G. New approaches to vaccine development: memorandum from a WHO meeting. Bulletin of the World Health Organization.1985; 63(3):479-484.
28. Ada GL. What to expect of a good vaccine and how to achieve it. Vaccine. 1988; 6(2):77-89.
29. Allen PM. Antigen processing at the molecular level. Immunology Today. 1998; 8(9):270-273.
30. Allen PM, Matsueda GR, Evans RJ, Dunbar Jr JB, Marshall GR, Unanue ER. Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature. 1987; 327(6124):713-722.
31. Arnon R. Peptides as immunogens: prospects for synthetic vaccines. In Peptides as Immunogens. Springer, Berlin, Heidelberg. 1986; 5:1-12.
32. Arnon R. Synthetic peptides as the basis for future vaccines. Trends in Biochemical Sciences. 1986; 11(12):521-524.
33. Arnon R, Shapira M, Jacob CO. Synthetic vaccines. Journal of immunological methods. 1983; 61(3):261-273.
34. Atassi MZ, Casali P, Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 1988; 41(2):123-132.
35. Dewangan HK, Pandey T, Singh S. Nanovaccine for immunotherapy and reduced hepatitis-B virus in humanized model. Artificial cell nanomedicine and biotechnology. 2018; 46(8):2033–2042.
36. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature. 1985; 317(6035):359-363.
37. Pintar A, Carugo O, Pongor S. CX, an algorithm that identifies protruding atoms in proteins. Bioinformatics. 2005; 18(7):980-984.
38. Beck E, Strohmaier K. Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. Journal of Virology. 1987; 61(5):1621-1629.
39. Dewangan HK, Pandey T, Mourya L, Singh S. Rational design and evaluation of HBsAg polymeric nanoparticles as antigen delivery carriers. International Journal of Biological Macromolecules. 2018; 111:804–812
40. Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomedicine. 2013; 1(1):1-12.
41. Rathore P, Swami G. Virosomes: a novel vaccination technology. International Journal of Pharmaceutical Sciences and Research. 2012; 3(10):3591.
42. Cabral H, Kataoka K. Multifunctional nanoassemblies of block copolymers for future cancer therapy. Science and technology of advanced materials. 2010; 11(1):104-113.
43. Mohapatra SS. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. The Pediatric infectious disease journal. 2003; 22(2):S100-S104.
44. Ssemaganda A, Giddam AK., Zaman M, Skwarczynski M, Toth I, Stanisic DI, Good MF. Induction of Plasmodium-specific immune responses using liposome-based vaccines. Frontiers in immunology. 2019; 10:231-242.
45. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. The Journal of Immunology. 2006; 176(12):7335-7345.
46. Ali AA, McCrudden CM, McCaffrey J, McBride JW, Cole G, Dunne NJ, McCarthy HO. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomedicine: Nanotechnology, Biology and Medicine. 2017; 13(3):921-932.
47. Dewangan HK, Maurya L, Srivastava A, Singh S. Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulatio Optimization and In-vivo Immunization in BALB/c Mice. Curr Drug Deliv. 2017; 15(8):1204-1215
48. Dhakal S, Cheng X, Salcido J, Renu S, Bondra K, Lakshmanappa YS, Misch C, Ghimire S, Feliciano-Ruiz N, Hogshead B, Krakowka S, Carson K, McDonough J, Lee CW, Renukaradhya GJ. Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs. Int J Nanomedicine. 2018; 13:6699–6715.
49. Broecker F, Götze S, Hudon J, Dominea CK, Pereira CL, Stallforth P, Anish C, Seeberger PH. Synthesis, Liposomal Formulation, and Immunological Evaluation of a Minimalistic Carbohydrate-?-GalCer Vaccine Candidate. J. Med. Chem. 2018; 61(11):4918–4927.
50. Hidaka A, Kiyono H, Kunisawa J, Aramaki Y. Intranasal administration of cationic liposomes enhanced granulocyte–macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity. BMC Res Notes. 2018; 11(1):472-483.
51. Qu W, Li N, Yu R, Zuo W, Fu W, Fei W, Hou Y. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitroinduces potent humoural immunity. Artificial Cells, Nanomedicine, and Biotechnology. 2018; 46:S852-S960.
52. O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 -an innately attractive adjuvant formulation. Vaccine. 2012; 30(29):4341–4348.
53. Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine. 1999; 18(5–6):434–439.
54. De Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN. The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. Vaccine. 2010; 28(40):6597–6602.
55. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990; 7(2):167–169.
56. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine. 2011; 29(33):5434–5442.
57. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005; 6(8):769–776.
58. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009; 462(7272):449–460.
59. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010; 10(11)787–796.
60. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006; 112(1):26–34.
61. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008; 38(5):1404–1413.
62. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol. 2012; 188(8):3724–3733.
63. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective. J Clin Invest. 2001; 108(3):415–423.
64. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci USA. 2012; 109(4):1080–1085.
65. Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014; 40(5):642–656.
66. Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 2012; 33(2):71–77.
67. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007; 7(10):790–802.
68. Garçon N, Chomez P, Van Mechelen M. Glaxo- SmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6(5):723–739.
69. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011; 12(6):509–517.
70. Sporri R, Reis-e-Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol. 2005; 6(2):163–170.
71. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 2005; 438(7066):364–368.
72. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines, J Clin Invest. 2016; 126(3):7999-808.
73. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006; 440(7085):808–812.
74. Steers NJ, Peachman KK, McClain S, Alving CR, Rao M. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. Vaccine. 2009; 27(49):6939–6949.
75. Stano A, van der Vlies AJ, Martino MM, Swartz MA, Hubbell JA, Simeoni E. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine. 2011; 29(4):804–812.
76. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol. 2007; 25:419–441.
This work is licensed under a Creative Commons Attribution 4.0 International License.